Applied Radiation and Isotopes 2011-12-01

Low dose of gamma irradiation enhanced boronophenylalanine uptake in head and neck carcinoma cells for boron neutron capture therapy.

Y C Lin, S J Wang, H P Chung, H M Liu, F I Chou

Index: Appl. Radiat. Isot. 69(12) , 1728-31, (2011)

Full Text: HTML

Abstract

This study attempted to increase the boron uptake of human head and neck carcinoma SAS cells for BNCT by using a gamma dose of 0.1 Gy for combined treatment. Intracellular boron concentrations in 25 μgB/mL medium of BPA treated and BPA combined gamma-irradiation treated SAS cells were 73.8±1.73 and 95.15±1.36 ppm, respectively. After neutron irradiation, the G2/M-phase cell populations of untreated, BPA treated and BPA combined gamma-irradiation treated SAS cells were 19.31±1.71%, 52.47±2.25% and 59.19±2.63%, respectively. Experimental results indicate that the low dose gamma radiation with combination BPA treatment has the highest killing rate after neutron irradiation. Capable of significantly increasing the G2/M arrest after neutron irradiation, the combined treatment of a low dose of gamma irradiation with 25 μg B/mL medium of BPA also provided a higher killing effect for BNCT.Copyright © 2011 Elsevier Ltd. All rights reserved.

Related Compounds

  • 4-Borono-L-phenyl...

Related Articles:

Pharmacokinetic analysis and uptake of 18F-FBPA-Fr after ultrasound-induced blood-brain barrier disruption for potential enhancement of boron delivery for neutron capture therapy.

2014-04-01

[J. Nucl. Med. 55(4) , 616-21, (2014)]

Boron neutron capture therapy induces apoptosis of glioma cells through Bcl-2/Bax.

2010-01-01

[BMC Cancer 10 , 661, (2010)]

Studies for the application of boron neutron capture therapy to the treatment of differentiated thyroid cancer.

2011-12-01

[Appl. Radiat. Isot. 69(12) , 1752-5, (2011)]

Boron neutron capture therapy for clear cell sarcoma (CCS): biodistribution study of p-borono-L-phenylalanine in CCS-bearing animal models.

2011-12-01

[Appl. Radiat. Isot. 69(12) , 1721-4, (2011)]

EORTC trial 11001: distribution of two 10B-compounds in patients with squamous cell carcinoma of head and neck, a translational research/phase 1 trial.

2009-08-01

[J. Cell. Mol. Med. 13(8B) , 1653-65, (2009)]

More Articles...